This is a multicenter study to evaluate potential decrease in hospitalization events and time between events and increasing longevity in patients with symptomatic congestive heart failure and intolerant of first-line medication for heart failure. This study will evaluate if higher doses of the investigational drug given daily will be superior to the lower dose of the same investigational drug given daily.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
3,834
50-mg losartan oral tablet
100-mg losartan oral tablet + 50-mg losartan oral tablet
Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure
Time frame: Entire follow-up (median = 4.7 years)
Number of Participants That Experienced One Components of the Composite Clinical Endpoint of All Cause Death or Cardiovascular Hospitalization
Cardiovascular hospitalization is defined as any hospitalization that may be attributed to a cardiovascular cause, including heart failure.
Time frame: Entire follow-up (median = 4.7 years)
Number of Participants That Died (Any Cause)
Time frame: Entire follow-up (median = 4.7 years)
Number of Participants That Were Hospitalized for Heart Failure
Time frame: Entire follow-up (median = 4.7 years)
Number of Participants That Experienced Cardiovascular Hospitalization
Time frame: Entire follow-up (median = 4.7 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.